Colorado Animal Specialty & Emergency (CASE)
Evaluation of field effectiveness and safety of Voclosporin 2 mg/mL Ophthalmic Solution
CURRENTLY ENROLLING
SUMMARY OF STUDY:
This randomized, double-masked, placebo-controlled field study will assess once-daily VOS versus placebo in improving tear production and reducing clinical signs of KCS. Effectiveness will be based on improvements in Schirmer Tear Test (STT) results and clinical scoring through Day 28, with continued safety follow-up through Day 84.
INCLUSION CRITERIA:
Dogs ≥ 6 months old with a diagnosis of KCS.
STT ≥ 2 mm/min and ≤ 10 mm/min in one or both eyes.
At least 2 of 3 conjunctival signs scored ≥ 2 (redness, discharge, conjunctival swelling).
Owners willing to administer daily drops and attend all visits.
Stable chronic conditions permitted if not on prohibited medications.
Keratoconjunctivitis sicca (KCS)/dry eye in one or both eyes
FINANCIAL INCENTIVES:
Participating pet owners will receive:
Screening testing including physical and eye exams, bloodwork, and urinalysis are covered financially. Once enrolled, owners will be sent home daily treatments to start the same day. An owner's diary is required to be filled out to monitor any side effects. Study is fully funded, with no cost to the owners.
WHAT TO EXPECT:
Participating patients will be required to complete a standard pre-enrollment screening that involves a physical exam, ophthalmic exam, bloodwork, and urinalysis. Dogs are seen for a total of 5 visits over the course of 84 days. Daily eye treatments are given at home by owner with documentation in a daily diary with noted date, time and which eye the treatment was given. Return diaries to the site during your next visit. Return all used and unused droppers and treatments to the site at each visit.
INTERESTED?
Email [email protected]
